Navigation Links
Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders
Date:4/21/2011

>
  • Additionally, Valeant's stated 24% premium to Cephalon's closing price as of March 29, 2011 is significantly below the 59% 30-day and 48% 1-day median acquisition premium for U.S. life-science acquisitions since 2006.  Valeant's 0.4% premium to Cephalon's 52-week high between March 29, 2010 and March 29, 2011 of $72.87, is also far below the median 20% premium to 52-week highs of U.S. life-science acquisitions since 2006.(1)

  • As a Bloomberg article recently noted, "The $73 a share bid valued the transaction at $5.46 billion including net debt, data compiled by Bloomberg show. At that price, the deal is 5.3 times Cephalon's trailing EBITDA of $1.04 billion last year, the data show. That's 65 percent lower than the median 15.1 times for all drug takeovers over $1 billion."(2)

    Cephalon has created a broad pipeline, with 10 late-stage product candidates targeted at novel and "best-in-class" therapeutics.(3)  Your Board and management team have a proven history of developing late-stage compounds such as PROVIGIL, NUVIGIL, FENTORA and TREANDA, among others.  Your Board believes these programs represent significant value that is not reflected in Valeant's $73 per share proposal, but which Valeant would seek to capture for itself either on its own or through transactions with third parties.

    As Valeant's CEO has publicly stated, Valeant is estimating synergies of $300 million in the proposed transaction with Cephalon.  In Valeant's 2010 merger with Biovail, Valeant initially announced $175 million of synergies but ultimately identified synergies in excess of $300 million, or almost double its estimate.  If this pattern holds true, Valeant's synergies in a Cephalon transaction could greatly exceed Valeant's predictions.  These incremental synergies are indicative of the value that Valeant would like to keep fully for its shareholders by paying an inadequate price to Cephalon shareholders.

    Valeant is also impo
    '/>"/>

    SOURCE Cephalon, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Cephalon Quarterly Conference Call Invitation
    2. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
    3. $425 Million Cephalon Civil Settlement and Criminal Fine; In Americas Largest
    4. Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
    5. Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
    6. Cephalon Reports Another Strong Quarter
    7. Cephalon, Inc. to Webcast Analyst Day
    8. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
    9. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
    10. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
    11. Cephalons New Product Launches Pace Record 2008 Sales
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2015)... YORK , July 28, 2015 Deerfield ... Deerfield Healthcare Innovations Fund, L.P., which will invest in ... interventions in genetic diseases, cancer, and orphan diseases. The ... can transform how therapeutics are developed and improve the ... fund, one of the largest healthcare-focused venture funds in ...
    (Date:7/28/2015)... NEWPORT BEACH, Calif. , July 28, 2015 ... company, announced that it has hit a milestone ... Putty. Signafuse was FDA 510(k) cleared in early ... standalone use in posterolateral spine fusion procedures.  This ... graft products, as less than 6% of new ...
    (Date:7/28/2015)... Israel , July 28, 2015 ... medicine company utilizing its proprietary plant-based rhCollagen technology ... Shurtz has been appointed Senior Director of Business ... (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ) , ... in marketing, regulatory and business strategy. Prior to ...
    (Date:7/27/2015)... , July 27, 2015 /PRNewswire/ - Quest PharmaTech Inc. ... developing and commercializing products for the treatment of cancer, ... announces that it has closed a $1,000,000 unit offering ... of 16,666,667 units of the Company at a price ... one common share and one common share purchase warrant.  ...
    Breaking Biology Technology:Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3Revolutionary Bone Graft Exceeds Expectations 2CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Quest PharmaTech Closes $1,000,000 Private Placement 2
    ... ATHENS, Ga., March 23 ArunA Biomedical, ... Inc. of Edina, MN, giving Neuromics the right ... Human Neural Cells and Neural Culture Medium to ... )ArunA has an exclusive worldwide license to ...
    ... Horizon Therapeutics, a privately held biopharmaceutical company ... executive officer will present at InsideVenture,s Debut Conference, ... Therapeutics has been selected from over 170 nominations ... showcased to long-term investors through presentations and 1-on-1 ...
    ... Ohio, March 23 NanoLogix announces that veteran journalist ... in advance of major news. Scanlon,s addition to ... information flow to investors and media, and will aid ... Bill Scanlon brings 25 years of experience in ...
    Cached Biology Technology:ArunA Biomedical, Inc. Announces Alliance with Neuromics for Distribution of Normal Human Neural Cells 2Horizon Therapeutics Selected to Present at InsideVenture's Debut Investor Conference March 25-26, Santa Barbara, California 2Horizon Therapeutics Selected to Present at InsideVenture's Debut Investor Conference March 25-26, Santa Barbara, California 3NanoLogix Adds Noted Journalist Bill Scanlon to Provide Media Relations 2
    (Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/188684 for BEHAVIORAL-DIRECTED ... another new convenient and secure method to make ... innovative payment methods, introduced with its groundbreaking voice-direct ...
    (Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
    (Date:7/9/2015)... JOSE, Calif. , July 9, 2015 ... the leading developer of human interface solutions, ... technology, the industry,s first fully hardware encapsulated ... Match-in-Sensor secure authentication technology is literally off ... storage and biometric matching within the fingerprint ...
    Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
    ... Lukiw, PhD, Associate Professor of Neuroscience and Ophthalmology ... lead author of a paper identifying, for the first ... acid (RNA), once thought to be no more than ... Alzheimer,s disease. The paper, An NF-kB-sensitive micro RNA-146a-mediated inflammatory ...
    ... Americans have headed to the polls to elect their next ... Current Biology , a Cell Press publication, reveals how ... time they reach a consensus to go for the more ... stickleback fish preferred to follow larger over smaller leaders," said ...
    ... CHARLOTTESVILLE, VA (November 13, 2008) In a report now ... the December 2008 issue of the Journal of Urology, ... PhD and his colleagues have confirmed the accuracy and reliability ... for detecting low concentrations of sperm. Herr, a ...
    Cached Biology News:LSUHSC research identifies key contributor to Alzheimer's disease process 2Fish choose their leaders by consensus 2Fish choose their leaders by consensus 3First at-home test for vasectomized men proves to be safe, accurate 2
    Rab1A...
    Drugs and NO-drug Rat Anti-conjugated Acetyl Salicylic Acid Polyclonal Antibody...
    Applications: Beadlyte® assay Stability: 2 years at 4°C (lyophilized) or 6 months at -20°C (rehydrated) ...
    ... Product Mouse monoclonal [SPM278] to ... Small cell lung carcinoma N592 live cells ... with Human. Not yet tested in other ... of the major glycoproteins of basement membrane, ...
    Biology Products: